Welcome to our dedicated page for Rapid Dose Thera news (Ticker: RDTCF), a resource for investors and traders seeking the latest updates and insights on Rapid Dose Thera stock.
Rapid Dose Therapeutics Corp. (RDTCF / CSE: DOSE) is a Canadian biotechnology and life sciences company centered on its QuickStrip™ oral thin-film drug delivery platform. The news flow around the company frequently combines product development updates with financing and corporate actions, giving investors insight into both its technology progress and its capital structure.
Readers of this news page can follow announcements on QuickStrip™-based initiatives, including nicotine-focused products such as QuickStrip™ Nicotine and NicStrip™, as well as harm reduction applications like the Replace+ sublingual cannabis strip developed with Eco Canadian Organic Inc. News releases have covered regulatory milestones such as a Health Canada submission for QuickStrip™ Nicotine in multiple dose strengths and details of a pharmacokinetic clinical study comparing nicotine absorption to combustible cigarettes.
In addition to product and partnership updates, Rapid Dose Therapeutics regularly reports on financing-related developments. These include private placement financings involving secured convertible notes and warrants, extensions of note maturities and warrant expiries, and the issuance of common shares to pay accrued interest on secured debt. The company has also disclosed shares-for-debt transactions with creditors and directors aimed at reducing outstanding liabilities.
By reviewing the news items linked on this page, investors and observers can track how Rapid Dose Therapeutics advances its QuickStrip™ technology across nicotine, cannabis, nutraceutical and pharmaceutical applications, while also monitoring share issuances, note terms and other corporate actions that affect its capital structure. This page is a central source for the company’s publicly released updates and disclosures.
Rapid Dose Therapeutics (CSE: DOSE) announced plans to issue common shares to satisfy the quarterly interest payment due December 31, 2024, on its secured convertible notes. The company will issue 430,930 common shares at $0.22 per share to cover $94,806.23 in accrued interest.
This share issuance stems from the company's previous private placement financing, where RDT issued $3,134,445 in principal amount of Notes and 15,672,225 Warrants in 2023. The Notes, maturing on November 30, 2025, carry a 12.0% annual interest rate, payable quarterly in common shares. The share price is determined by the closing market price on the CSE at each quarter's end.
The newly issued shares will be subject to a four-month and one-day hold period from their issue date, expected no later than January 15, 2025.
Rapid Dose Therapeutics (CSE: DOSE) has announced a shares-for-debt transaction with its five non-management directors to settle outstanding director fees. Each director is owed $10,000 for three fiscal quarters (May 31, August 31, and November 30, 2024), totaling an aggregate debt of $150,000.
The company will issue common shares at a price equal to the closing market price on December 31, 2024, with expected issuance around January 15, 2025. The shares will be subject to a four-month hold period. This transaction aims to improve RDT's financial position by reducing existing liabilities. No new control person will be created through this transaction.
Rapid Dose Therapeutics (CSE: DOSE) has announced a proposed equity private placement financing aiming to raise up to $6,000,000 through the issuance of up to 24,000,000 units at $0.25 per unit. Each unit includes one common share and one warrant exercisable at $0.33 for two years.
The company plans to use the proceeds for debt retirement, research and development, capital expansion, and working capital. Meadowbank Asset Management will serve as the agent, receiving a 1% cash commission and 6% in agent warrants.
Additionally, RDT plans to settle up to $400,000 in debt through the issuance of up to 1,600,000 common shares at a minimum price of $0.25 per share to improve its financial position.
Rapid Dose Therapeutics Corp. (CSE: DOSE) has filed a patent application for its Lidocaine Oral Thin Film Strip with the Canadian Intellectual Property Office. The innovative product offers an alternative to traditional dental anesthesia methods, delivering lidocaine through a dissolvable strip that adheres to oral mucosa.
The Lidocaine QuickStrip™ provides precise application, complete dissolution, and efficient absorption. It can be used for various dental applications, including pre-procedure anesthesia and post-operative pain control. The product aims to reduce patient anxiety and save dentists' chair time by eliminating the traditional needle administration process, which typically takes up to five minutes with conventional methods.
Rapid Dose Therapeutics Corp. (CSE: DOSE) has completed the second and final tranche of its equity private placement financing, raising $542,000 through the issuance of 3,188,233 common shares at $0.17 per share. Combined with the first tranche, the company has raised total gross proceeds of $851,000. The financing had a maximum capacity of $6,000,000. Proceeds will support research and development, capital expansion, debt repayment, and working capital needs. The issued shares are subject to a four-month hold period.
Rapid Dose Therapeutics Corp. (CSE: DOSE) has announced its intention to issue common shares to satisfy accrued interest on its secured convertible notes and Madison Debt. The company plans to issue 557,677 common shares at $0.17 per share to noteholders, covering $94,806.23 in accrued interest. Additionally, 39,996 common shares will be issued to Madison Partners for $6,799.37 in accrued interest on the Madison Debt. These shares are expected to be issued by October 15, 2024.
The secured convertible notes, part of a private placement financing, have a maturity date of November 30, 2025 and bear 12.0% annual interest. The company previously issued $3,134,445 in principal amount of notes and 15,672,225 warrants. All common shares issued as interest payment will be subject to a four-month and one-day hold period from the date of issue.
Rapid Dose Therapeutics Corp. (CSE: DOSE) has received an extension from the Canadian Securities Exchange for its proposed equity private placement financing. The company now has until October 29, 2024 to close the Financing, which aims to raise up to $6,000,000 in gross proceeds. The Financing involves issuing up to 35,294,117 common shares at $0.17 per share.
The Financing may close in multiple tranches, with the first tranche of $309,000 already closed on July 18, 2024. All securities issued will be subject to a four-month hold period from the applicable closing date, in compliance with securities laws.
Rapid Dose Therapeutics Corp. (CSE: DOSE) has successfully closed the first tranche of its previously announced equity private placement financing, raising $309,000 in gross proceeds. The company issued 1,817,647 common shares at a price of $0.17 per share. This is part of a larger financing effort that allows for a maximum of $6,000,000 in gross proceeds, consisting of up to 35,294,117 common shares.
The funds will be utilized for research and development, capital expansion, debt repayment, and general working capital requirements. The issued shares are subject to a four-month hold period from the closing date, in compliance with applicable securities laws.
Rapid Dose Therapeutics (RDT) announced its plan to issue common shares to pay accrued interest on its secured convertible notes and other debt obligations. The company aims to issue 520,968 shares at $0.18 each to satisfy $93,775.72 of interest on its notes. Additionally, 41,968 shares will be issued to Madison Partners for $7,554.28 of interest on a $250,000 debt. These shares will be issued no later than July 15, 2024, and will be subject to a holding period of four months and one day.
The notes, which mature on November 30, 2025, have an annual interest rate of 12%, calculated monthly and payable quarterly in shares. The financing included $3,134,445 in notes and 15,672,225 warrants.
Rapid Dose Therapeutics (RDT) has released its fiscal year 2024 financial results, highlighting a 42% increase in revenue to CAD$1,020,424. Despite this growth, the company reported a net comprehensive loss of CAD$4,287,578, a 12% increase from the previous year. Operating expenses rose by 3% to CAD$4,305,157, but non-cash charges decreased by 42% to CAD$782,559.
Key operational milestones include developing a Canadian retail base for nutraceutical products, entering a pharmaceutical collaboration to create QuickStrips for dental anesthesia, and initiating a pre-commercialization project for nicotine oral thin film strips. RDT also participated in an NFL-funded clinical trial for cannabinoid-based pain management. Regulatory delays continued to pose challenges, but post-year-end approvals for nutraceutical and cannabis products in Canada were achieved.